Vivo Capital

Founded 1996
Founders Edgar G. Engleman Frank Kung

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 155
Average round size
info
The average size of a deal this fund participated in
$51M
Portfolio companies 111
Rounds per year 6.20
Lead investments 26
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.32
Exits 65
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

In 1997 was created Vivo Capital, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the Palo Alto.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vivo Capital, startups are often financed by Sofinnova Investments, OrbiMed, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Frazier Healthcare Partners, Aisling Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Aisling Capital, Technology Partners.

The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline ZAI Lab, Harmony Biosciences, Passage Bio Among the most popular fund investment industries, there are Medical, Genetics.

This organization was formed by Edgar G. Engleman. The overall number of key employees were 11.

Comparing to the other companies, this Vivo Capital performs on 11 percentage points more the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually. When the investment is from Vivo Capital the average startup value is 100-500 millions dollars. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Vivo Capital:
Typical Co-investors
Vivo Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Vivo Capital:

Funds with similar focus

Funds from United States, Palo Alto
Funds with similar focus located in United States, Palo Alto:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Pall United States, Port Washington
NexGen Energy Canada, Vancouver
Rosario Capital LTD Israel, Tel Aviv
MorphoSys Germany, Planegg
Actium Funds United States, Salt Lake City
Xuebao No.1 China, Haidian
Kun Lun Stone Capital China, Shenzhen
RRC Group Russia, Moscow
Xin Chang Electronics Technology -
Dingqing Investment China, Beijing
TriplePoint Ventures United States, Menlo Park
Vertex Asia Fund Russia, Moscow
Cognosante United States, McLean
Capital Fund Management France, Paris
Q Investments United States, Fort Worth
The Optimas Group United States, Omaha
Varsity Ventures United States, Stanford
Grit Ventures United States, Menlo Park
New Science Ventures United States, New York
Rubicon Venture Capital United States, San Francisco

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Attralus

Biopharma
Biotechnology
Health Care
Medical
1
$116M08 Sep 2021 United States, San Francisco

Neurogastrx

Biotechnology
Health Care
Health Diagnostics
Pharmaceutical
1
$60M26 Aug 2021 United States, " United States"}

Biotechnology
1
$200M26 May 2021

Rgenta Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
1
$18M25 May 2021 United States, Cambridge

Larimar Therapeutics

Biotechnology
Medical
Therapeutics
n/a
$95M21 May 2021 United States, Lower Merion Township

Sera Prognostics

Biotechnology
Health Care
Hospital
Medical
Medical Device
1
$100M28 Apr 2021 United States, Salt Lake City

Health Care
Medical Device
Robotics
1
23 Apr 2021 China, Shanghai

Biopharma
Biotechnology
Health Care
Medical
Therapeutics
1
$73M30 Mar 2021 United States, Palo Alto

Fortis Therapeutics

Biotechnology
Therapeutics
1
$40M29 Mar 2021 United States, San Diego
News
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital. – Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors. – Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions... Read more
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X. – Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others. – The targeted radiopharma... Read more

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vivo Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: